Danaher (DHR) Stock Looks Fully Priced Despite Its 18% Three Year Gain

Danaher has delivered an 18.1% gain over the past three years, and the question now is whether that share price level matches what its cash flows can reasonably support. Recent product clearances in its diagnostics and life sciences units add fresh information for investors who are trying to anchor Danaher's valuation to the cash coming off the business rather than the headlines.

• The stock's 18.1% return over three years places greater focus on whether the underlying cash generation is strong enough to back that move.

• New FDA cleared tests at Cepheid and Beckman Coulter can influence how quickly Danaher converts its research spending into revenue and, eventually, cash in the door.

• What if you looked at Danaher through its earnings instead? See what Danaher's 37.7x P/E says about the price .

The issue now is whether today's price for Danaher is adequately supported by the intrinsic value suggested by its cash flows.

If you want a wider watchlist of companies where valuation work starts with cash coming through the door, a focused screener of 35 high quality undervalued stocks is a useful next step.

Where Does Danaher Sit on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash Danaher can return to shareholders over time rather than headline earnings. Latest twelve month free cash flow is about $5.6b, and the projections assume that this pool of cash continues growing from that base rather than shrinking.

Analyst and model estimates point to higher free cash flow by 2030, followed by slower expansion after that. This fits a business that already produces sizeable surplus cash rather than one still in heavy build out mode. Because the DCF outcome is broadly in line with the current share price of $230.11, the market is already treating Danaher as a mature cash generator without baking in an aggressive acceleration. Beckman Coulter's newly cleared rapid bacterial versus viral assay helps explain why investors are comfortable paying that kind of price for the future cash stream. Find out what Danaher could be worth using our Discounted Cash Flow (DCF) estimate .

The Danaher Narrative: What Would Justify Today's Price?

Danaher's Simply Wall St Narratives pick up where the cash flow puzzle leaves off and explain which paths for growth, profitability and earnings would need to occur for the valuation to look meaningfully higher or lower than today's price. Each scenario connects its number to a specific view on how Danaher's growth, margins and exposure to risk might evolve, providing a reference point you can revisit as new information appears on the Community page.